The largest cell therapy trials in medicine have been run in cardiac disease. Most did not meet their primary endpoints. Here is the record.
## ⚠️ Cardiac symptoms are time-critical
Call emergency services immediately for chest pain or pressure, pain spreading to the arm, neck or jaw,
sudden breathlessness, breathlessness at rest, fainting, or a racing or irregular heartbeat with dizziness.
Heart attack treatment works in hours, not days, and every minute of delay costs heart muscle that cannot
be recovered.
**Nothing on this page is an alternative to emergency care, to revascularisation, to implanted device therapy,
or to the medication your cardiologist has prescribed** — and nothing here is a reason to delay or stop any
of them. Guideline-directed medical therapy for heart failure saves lives. Cell therapy has not been shown to.
Heart Disease and What Already Works
Coronary artery disease — narrowing of the coronary arteries, reducing blood flow to heart muscle, and the leading cause of heart attacks.
Heart failure — the heart cannot pump effectively. Chronic and progressive. Affects more than 6 million adults in the United States [1].
Cardiomyopathy — disease of the heart muscle itself, with reduced pumping ability and several causes.
Post-infarction damage — scar tissue replaces dead muscle, reducing function and raising arrhythmia risk.
The standard of care, and why it matters here
This is the treatment against which anything new must be judged, and it is one of the genuine successes of modern medicine.
For heart failure with reduced ejection fraction, four drug classes have each been shown in large randomised trials to reduce mortality, and are used together as "guideline-directed medical therapy":
- Beta-blockers
- ACE inhibitors, angiotensin receptor blockers, or angiotensin receptor–neprilysin inhibitors (ARNI)
- Mineralocorticoid receptor antagonists
- SGLT2 inhibitors
Alongside these: statins and antiplatelet therapy for coronary disease; implantable cardioverter-defibrillators to prevent sudden cardiac death in selected patients; cardiac resynchronisation therapy for those with conduction delay; revascularisation by stenting or bypass; valve repair or replacement; and transplantation or mechanical support in end-stage disease.
⚠️ The effect sizes for these therapies are large and well established, and the specific figures belong in a conversation with your cardiologist rather than on a web page. What matters for reading the rest of this article is the comparison: every cell therapy trial below enrolled patients who were already on optimal medical therapy. Cell therapy has only ever been tested as an addition to that foundation — never as a replacement for it.
What Cell Therapy Is Proposed to Do
The mechanisms under investigation are:
- Paracrine signalling — release of growth factors and anti-inflammatory mediators that may protect surviving myocardium [3]
- Angiogenesis — promotion of new blood vessel formation in ischaemic tissue
- Modulation of scar and remodelling — influencing how the ventricle remodels after injury [3]
- Immunomodulation — shifting the balance of inflammatory signalling in the myocardium [2]
⚠️ A mechanism you will still see quoted elsewhere is not on that list. The proposition that infused cells stimulate resident cardiac stem cells to regenerate myocardium rested on a body of work — including the retracted trial discussed below — that did not survive independent scrutiny. It is not a supportable mechanism of action, and any source still offering it as one is working from a superseded model.
What the Trials Actually Found
Cardiac disease has attracted more cell therapy investment than any other indication. The trials below are real, large and well conducted. Reporting them honestly means reporting which endpoint was primary and whether it was met — which is the part most summaries leave out.
⛔ A retracted trial, and what it means
SCIPIO — a phase 1 trial of autologous "cardiac stem cells" in ischaemic cardiomyopathy, published in The Lancet in 2011 — is retracted. It is no longer part of the scientific record and cannot be cited as evidence of feasibility, safety or cardiac regeneration.
Its retraction sits within a wider correction: the concept of c-kit-positive resident cardiac stem cells capable of regenerating myocardium, once the field's most exciting proposition, did not survive independent scrutiny. A substantial portion of the early enthusiasm for cardiac cell therapy rested on that model.
This matters for reading everything else: when a field's founding mechanism is withdrawn, the trials built on it need reassessing, and claims about "cardiac regeneration" require more scepticism than claims about paracrine effects.
Transendocardial and intramyocardial delivery
POSEIDON compared allogeneic versus autologous bone-marrow MSCs delivered by transendocardial injection in ischaemic cardiomyopathy [4]. It established that both approaches were feasible and tolerated, and was designed as a comparison between cell sources rather than against placebo.
POSEIDON-DCM extended the comparison to non-ischaemic dilated cardiomyopathy, reporting functional improvements with allogeneic cells [5].
DREAM-HF is the largest trial in the field: 565 patients with chronic heart failure receiving allogeneic mesenchymal precursor cells by a single intramyocardial administration.
The publication cited here is a secondary analysis, and its own title says so: "Mesenchymal precursor cells reduce mortality and major morbidity in ischaemic heart failure with inflammation" [2]. What it reports:
- In control patients, the strongest predictors of cardiovascular death were inflammation (baseline hs-CRP ≥ 2 mg/L; p = 0.003, 61% increased risk) and ischaemic aetiology (p = 0.097, 38% increased risk)
- Over a mean 30 months, in patients with both ischaemic heart failure and inflammation, cells reduced 2-point MACE by 88% (p = 0.005) and 3-point MACE by 52% (p = 0.018) versus controls
⚠️ Read that carefully. These are large effects in a defined subgroup identified after the fact, in a trial whose overall primary endpoint result is not what this paper reports. Subgroup findings of this kind generate the next trial; they do not establish efficacy. The appropriate description is "a striking signal that requires prospective confirmation in the population it identifies" — which is how the authors frame it.
Intracoronary delivery after myocardial infarction
LateTIME tested intracoronary autologous bone-marrow mononuclear cells delivered 2–3 weeks after acute myocardial infarction, examining effect on left ventricular function [6]. It was one of a pair of trials — the other, TIME, tested earlier delivery — investigating whether the timing of administration determined benefit.
These trials are important precisely because of what they showed about timing, and describing them only as having "demonstrated safety" omits their purpose and their result.
Skeletal myoblasts
MAGIC was the first randomised placebo-controlled trial of myoblast transplantation in ischaemic cardiomyopathy [7]. It is genuinely foundational as the first trial of its kind — and it did not establish efficacy. A trial's historical significance and its result are different things, and both belong in any account of it.
Intravenous delivery
RIMECARD was the first trial of intravenous umbilical-cord MSCs in heart failure — a phase 1/2 randomised controlled trial in 30 patients, reporting safety and improvement in ejection fraction [8]. Thirty patients, phase 1/2: a starting point rather than a result.
The pooled evidence
A Cochrane review examined autologous adult bone-marrow-derived stem or progenitor cells for chronic ischaemic heart disease and congestive heart failure, including 38 randomised controlled trials with 1,907 participants (1,114 receiving cells, 793 controls), with GRADE assessment of certainty [9]. Separate meta-analyses of human cell-based cardiac regeneration therapies [10]and of adult bone-marrow cell therapy [11]have reached broadly similar conclusions: modest effects on surrogate measures, with heterogeneity across cell types, doses, routes and timing that limits what can be pooled.
Effect sizes across this literature have been small, inconsistent between trials, and concentrated in surrogate endpoints such as ejection fraction rather than in mortality.
Delivery routes are different interventions
Evidence obtained by one route is not evidence for another.
Where This Leaves the Field
Not FDA-approved for any cardiac indication. Available in the United States only within clinical trials. Some products hold Regenerative Medicine Advanced Therapy designation, which accelerates review but is not approval.
Major cardiology societies — ACC, AHA and ESC — do not recommend cell therapy as standard of care for heart disease.
Reviews from within the field are candid about why. Comprehensive appraisals of the trial record [12][13]describe a two-decade programme that has produced consistent safety, inconsistent efficacy, and no therapy ready for practice — alongside continuing work on better cell types, better delivery and better patient selection [14].
Our Position
Sterling-certified partner clinics do not treat primary cardiac conditions with stem cells.
Why not:
- The evidence is still emerging, and the major trials have not established efficacy
- The risk profile is higher than for the applications we do offer — intramyocardial and intracoronary delivery are invasive procedures in patients with compromised hearts
- Guideline-directed medical therapy for heart disease is genuinely excellent, and nothing available in this field improves on it
- Patient safety comes first
What we do offer. For patients with orthopaedic or other conditions and stable heart disease, we evaluate case by case, require cardiology clearance, and modify protocols where appropriate. That is a decision about treating a different condition safely in someone who also has cardiac disease — not a cardiac treatment.
If Someone Offers You Cardiac Stem Cell Therapy
Red flags:
- Any clinic claiming to cure heart disease
- Treatment offered outside a registered clinical trial
- Pressure to decide quickly
- "Special access" or "compassionate use" framing outside a regulated pathway
- Any suggestion that this replaces, or allows you to reduce, your cardiac medication
Appropriate settings:
- Registered clinical trials at academic centres, with ethical approval
- Regulated facilities that are transparent about limitations
- Full cardiology oversight
Questions to ask:
- Is this a registered clinical trial? What is its identifier?
- What was the primary endpoint of the trial you are citing, and was it met?
- By what route would the cells be given, and what are the procedural risks?
- How does this interact with my current medication — and does anything change about it?
- Who manages my heart failure care during and after this?
Realistic Expectations
What cell therapy might do, on current evidence: a small improvement in cardiac function on imaging; some reduction in symptoms; possibly fewer hospitalisations in selected patients.
What it will not do: cure heart disease · replace transplantation · reverse established scar · work for everyone · substitute for guideline-directed medical therapy.
Who has been enrolled in trials: patients with stable chronic heart failure and reduced ejection fraction, already on optimal medical therapy, with realistic expectations.
Who has been excluded: acute heart failure · recent myocardial infarction (within 3 months) · unstable arrhythmias.
The Bottom Line
If you have heart disease:
- Follow standard medical care. It is the best-evidenced thing available to you, by a wide margin
- Consider a clinical trial if you are eligible and interested — that is where cell therapy belongs today
- Be wary of anyone selling this outside a trial
- Never reduce or stop cardiac medication on the basis of anything you read here
Cardiac cell therapy has had two decades, substantial funding, and some of the largest trials in regenerative medicine. It has established a reasonable safety record and produced one striking subgroup signal that deserves a proper prospective trial [2]. It has not produced a therapy. One of its foundational studies has been retracted.
That is not a reason to dismiss the field. It is a reason not to buy it yet — which is why we do not sell it.